Castle Bio Prices IPO at $16 per Share

Dec

Evolution of Tumor Profiling in a Clinical Lab: Moving toward Comprehensive Genomic Profiling

This webinar will provide a first-hand look at how a clinical lab evolved its tumor profiling workflow from a targeted panel approach toward comprehensive genomic profiling.

Jan

Featured Webinar

Comprehensive Profiling of Myeloid Malignancies with Reliable Detection of FLT3 and CEBPA

This webinar will discuss how Moffitt Cancer Center has implemented a new capture-based application to accurately assess myeloid malignancies by detecting complex variants in challenging genes in a single experiment.  

Menu

Castle Bio Prices IPO at $16 per Share

To read the full story....

Breaking News

Local Coverage Determinations Roundup: Transplant Genomics, Opko Health

Inspirata, DeePathology Partner on AI-Based H. Pylori Pathology Testing

BioMérieux, Beckman Coulter, Siemens Healthineers, Others Get 510(k) Clearances in November

Sienna Cancer Diagnostics Raises $1.1M in Private Placement

Spartan Bioscience, Angiocare Ink Distribution Deal for CYP2C19 Test

CDC Awards Aptagen $988K for Pork Tapeworm Test

Featured White Papers

Evolution of Tumor Profiling in a Clinical Lab: Moving toward Comprehensive Genomic Profiling

Comprehensive Profiling of Myeloid Malignancies with Reliable Detection of FLT3 and CEBPA

What's Popular?

NCCN Updates Genetic Testing Guidelines for Assessing Breast, Ovarian, Pancreatic Cancer Risk

FDA Approves Foundation Medicine CDx for Novartis Breast Cancer Drug Piqray

Hologic Vaginitis Tests Offer Improvements Over Gold Standard Methods

Veracyte Exclusively Licenses NanoString Diagnostic Platform for Up to $60M

Local Coverage Determinations Roundup: Transplant Genomics, Opko Health

Sponsorships